Results 181 to 190 of about 4,093 (216)

siRNAs targeting ANGPTL3 for mixed dyslipidemia

Med
The PROLONG-ANG3 trial demonstrated that two doses of solbinsiran, an siRNA targeting hepatic ANGPTL3, given 90 days apart, decreased concentrations of apoB, triglycerides, LDL-C, non-HDL-C, ANGPTL3, and hepatic fat content at day 180 in adults with mixed dyslipidemia.1 Long-term studies assessing the safety of solbinsiran and its efficacy in ...
openaire   +2 more sources

ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia

New England Journal of Medicine, 2017
Evinacumab, a monoclonal antibody that blocks ANGPTL3, was administered to nine adults with homozygous familial hypercholesterolemia. At 4 weeks, LDL cholesterol was reduced by a mean of 49%, with a mean absolute change from baseline of −157 mg per deciliter.
Daniel Gaudet, Daniel A. Gipe, Robert Pordy, Zahid Ahmad, Marina Cuchel, Prediman K. Shah, Kuang-Yuh Chyu, William J. Sasiela, Kuo-Chen Chan, Diane Brisson, Etienne Khoury, Poulabi Banerjee, Viktoria Gusarova, Jesper Gromada, Neil Stahl, George D. Yancopoulos, G. Kees Hovingh   +16 more
openaire   +1 more source

[Angptl3(angiopoietin-like 3)].

Nihon rinsho. Japanese journal of clinical medicine, 2004
Angiopoietin-like 3(Angptl3)-deficiency results in abnormally low lipid levels in mice. Angptl3-deficient mice showed enhanced very low density lipoprotein(VLDL) clearance compared with wild-type mice. Recombinant human ANGPTL3 protein inhibited lipoprotein lipase(LPL) activity in vitro, suggesting that Angptl3 affects VLDL triglyceride clearance by ...
Tetsuya, Shimizugawa, Yosuke, Ando, Mitsuru, Ono   +2 more
openaire   +1 more source

Oligonucleotides targeting ANGPTL3

International Journal of Cardiology, 2018
Fei, Luo, Yuan, Guo, Xiangping, Li, Xinqun, Hu, Zhenfei, Fang   +4 more
openaire   +2 more sources

Abstract Or121: Functional dissection of ANGPTL3

Arteriosclerosis, Thrombosis, and Vascular Biology
Dyslipidemia is a risk factor for metabolic diseases, emphasizing the importance of regulating lipoprotein metabolism. Levels of lipoproteins are regulated, in part, by extracellular lipases including lipoprotein lipase (LPL) and endothelial lipase (EL).
Sydney Walker, Kelli Sylvers, Alex Dou, Shwetha Shetty, Brandon Davies   +4 more
openaire   +1 more source

ANGPTL3 inhibition for hypercholesterolaemia

Nature Reviews Cardiology, 2020
openaire   +2 more sources

Is ANGPTL3 the next PCSK9?

Nature Reviews Endocrinology, 2017
Kiran Musunuru, Sekar Kathiresan
openaire   +1 more source

Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia

Journal of Clinical Medicine, 2023
, Stanisław Surma
exaly  

MICRORNA ANGPTL3 INHIBITOR

2021
ABUBAKER JEHAD, ABUFARHA MOHAMED, MULLA FAHD AL, ALKHAIRI IRINA, CHERIAN PREETHI   +4 more
openaire   +2 more sources

Transcriptomic Therapy for Dyslipidemias Utilizing Nucleic Acids Targeted at ANGPTL3

Future Cardiology, 2022
Dick Chan, Frederick Raäl
exaly